Abstract |
In this study, 16 eligible patients with intermediate and high-grade non-Hodgkin's lymphoma were treated with a new high-dose DHACT regimen supported by rhG-CSF and peripheral blood stem cell (PBSC) rescue. PBSC were mobilized by rhG-CSF or rhGM-CSF. Single leukapheresis was performed and the PBSC were then frozen in liquid nitrogen. CFU-GM clonogenic assay for mononuclear cells and resuscitated progenitor cells done to calculate how many progenitor cells were alive after freezing. The DHACT chemotherapy was composed of carboplatin 600 mg/m2 on d1, Ara-C 1500 mg/m2 on d2, VM-26 100 mg/m2 on d3, 4, and dexamethasone 40 mg/d, on d1-4. Autologous PBSC was reinfused after 24 to 48 hours of chemotherapy. Recombinant human G-CSF at 300 micrograms administered daily on 2 successive days when the absolute neutrophil count was greater than 1 x 10(9)/L. Other supportive care procedures were standard for the unit. The median amount of PBSC reinfused into a patient was 0.9 x 10(8)/kg. The recovery rate of CFU-GM was 78% after cryopresevation. Within 7 to 9 days after high-dose DHACT chemotherapy, the WBC count and the platlet count arrived nadir, and then rose gradually with rhG-CSF injection. The median time for WBC count from nadir to > or = 1 x 10(9)/L was 4 days, and that for platelet count from nadir to > or = 50 x 10(9)/L was 7 days. Nine patients achieved complete remission and 5 patients achieved partial remission. The median follow-up on survival was 9 months. High-dose DHACT regimen supported by rhG-CSF and PBSC rescue is a safe and effective treatment for patients with advanced intermediate and high-grade non-Hodgkin's lymphoma.
|
Authors | Y Ji, S Ji, X Ju |
Journal | Zhonghua zhong liu za zhi [Chinese journal of oncology]
(Zhonghua Zhong Liu Za Zhi)
Vol. 18
Issue 6
Pg. 471-5
(Nov 1996)
ISSN: 0253-3766 [Print] China |
PMID | 9387307
(Publication Type: Clinical Trial, English Abstract, Journal Article)
|
Chemical References |
- Recombinant Proteins
- Cytarabine
- Granulocyte Colony-Stimulating Factor
- Dexamethasone
- Granulocyte-Macrophage Colony-Stimulating Factor
- Teniposide
- Carboplatin
|
Topics |
- Adolescent
- Adult
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carboplatin
(administration & dosage)
- Combined Modality Therapy
- Cytarabine
(administration & dosage)
- Dexamethasone
(administration & dosage)
- Female
- Granulocyte Colony-Stimulating Factor
(therapeutic use)
- Granulocyte-Macrophage Colony-Stimulating Factor
(therapeutic use)
- Humans
- Lymphoma, Non-Hodgkin
(drug therapy)
- Male
- Middle Aged
- Recombinant Proteins
- Stem Cells
(physiology)
- Teniposide
(administration & dosage)
|